Jinyu Bio-Technology Co (SHSE:600201) Scaled Net Operating Assets: 0.64 (As of Mar. 2026)


SHSE:600201 Jinyu Bio-Technology Co Ltd SHSE:600201
68 GF Score
Price ¥12.31
GF Value ¥8.24
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Jinyu Bio-Technology Co Scaled Net Operating Assets?

Jinyu Bio-Technology Co SHSE:600201 +2.93% 68 Scaled Net Operating Assets is 0.64 as of Mar. 2026. GuruFocus rates SHSE:600201 with a GF Score™ of 68/100 and a GF Value™ of ¥8.24 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Jinyu Bio-Technology Co's operating assets for the quarter that ended in Mar. 2026 was ¥5,217 Mil. Jinyu Bio-Technology Co's operating liabilities for the quarter that ended in Mar. 2026 was ¥972 Mil. Jinyu Bio-Technology Co's Total Assets for the quarter that ended in Dec. 2025 was ¥6,612 Mil. Therefore, Jinyu Bio-Technology Co's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.64.

Jinyu Bio-Technology Co Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Jinyu Bio-Technology Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jinyu Bio-Technology Co Scaled Net Operating Assets Chart

Jinyu Bio-Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.59 0.61 0.62 0.62

Jinyu Bio-Technology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.66 0.65 0.62 0.64

SHSE:600201 vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Jinyu Bio-Technology Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jinyu Bio-Technology Co Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jinyu Bio-Technology Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Jinyu Bio-Technology Co's Scaled Net Operating Assets falls into.


SHSE:600201
68GF Score
Jinyu Bio-Technology Co Ltd SHSE:600201
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jinyu Bio-Technology Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Jinyu Bio-Technology Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(5226.508-1059.134)/6764.669
=0.62

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6611.572 - 1385.064
=5226.508

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1060.711 - 0.147 - 1.43
=1059.134

Jinyu Bio-Technology Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(5217.23-971.676)/6611.572
=0.64

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6536.935 - 1319.705
=5217.23

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=972.877 - 0.148 - 1.053
=971.676

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.64 mean?
Jinyu Bio-Technology Co (SHSE:600201) has a Scaled Net Operating Assets of 0.64 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Jinyu Bio-Technology Co and its competitors.
Is Jinyu Bio-Technology Co's Scaled Net Operating Assets too high?
Jinyu Bio-Technology Co's current Scaled Net Operating Assets is 0.64. Overall, Jinyu Bio-Technology Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinyu Bio-Technology Co's Scaled Net Operating Assets compare to VRTX and REGN?
Jinyu Bio-Technology Co's Scaled Net Operating Assets of 0.64 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Jinyu Bio-Technology Co and its competitors. Jinyu Bio-Technology Co's current Scaled Net Operating Assets is 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinyu Bio-Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co (SHSE:600201) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.24, compared to a current price of ¥12.31 — trading 49.4% above its estimated fair value. The current Scaled Net Operating Assets is 0.64. Jinyu Bio-Technology Co's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Jinyu Bio-Technology Co (SHSE:600201), the current Scaled Net Operating Assets is 0.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jinyu Bio-Technology Co (SHSE:600201) Overvalued in 2026?

Based on GuruFocus' analysis, Jinyu Bio-Technology Co stock appears to be overvalued. The current stock price of ¥12.31 is trading 49.4% above its estimated GF Value™ of ¥8.24. GuruFocus considers Jinyu Bio-Technology Co to be Significantly Overvalued.

Key valuation signals for SHSE:600201:

  • Scaled Net Operating Assets: 0.64
  • GF Value™: ¥8.24 vs. price of ¥12.31 (49.4% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jinyu Bio-Technology Co Business Description

Address No.1, Jinyu Street, Shaeryu Industrial Park, Economic and Technological Development Zone, Inner Mongolia Autonomous Region, Hohhot, CHN, 010030
Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.
68GF Score

Get the complete analysis for SHSE:600201

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥12.31
Price
¥8.24
GF Value